Get Ready for Hep C Meds Mavyret and Vosevi

You'll see home med lists that include new oral hepatitis C Rxs, Mavyret and Vosevi.

Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.

It'll also be the lowest priced...about $26,400/course compared to $94,500 for Harvoni or $75,000 for Epclusa for 12 weeks.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals